GlassScriptPhysician profile
William D Sanders
NPI 1679684823
$6,506.43
in general payments reported to CMS, 2019-2025
21 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $977 · 2022: $1,347 · 2023: $997 · 2024: $1,955 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,019 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,018.75 |
| Education | $163.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,007.34 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,483.03 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Alk-Abello, INC | $586.19 | 2021-2025 | Ragwitek, Grastek, Odactra |
| Blueprint Medicines Corporation | $471.69 | 2023-2025 | Ayvakit |
| Genzyme Corporation | $467.77 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $245.26 | 2021-2025 | |
| Genentech USA, INC. | $210.81 | 2024-2025 | Xolair |
| Glaxosmithkline, LLC. | $195.92 | 2021-2025 | Nucala |
| Grifols USA, LLC | $162.28 | 2021-2025 | Prolastin-C Liquid |
| Adma Biomanufacturing LLC | $150.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.03 | 2021-2025 | Cuvitru |
| Amgen INC. | $76.93 | 2022-2025 | Tezspire |
| Optinose US, INC. | $69.72 | 2021-2025 | |
| Phadia US INC. | $54.58 | 2024-2025 | Immunocap |
| Pharming Healthcare, INC. | $43.77 | 2024-2025 | Ruconest |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $40.23 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $36.84 | 2022 | |
| Pfizer INC. | $34.66 | 2022 | |
| Lilly USA, LLC | $32.03 | 2025 | Taltz, Ebglyss |
| Leo Pharma INC. | $25.19 | 2025 | Anzupgo |
| Eyevance Pharmaceuticals LLC | $18.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sanders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.